Labgenomics Co

Labgenomics Co EBIT Growth

The Year-over-Year EBIT Growth of Labgenomics Co (084650.KQ) as of Nov 5, 2026 is -238.24 %. In the previous year, Year-over-Year EBIT Growth was -110.07 % — a change of 116.45% (lower).

EBIT Growth

-238.24 %

YoY

116.45%

Last updated:

Year-over-Year EBIT Growth of Labgenomics Co is 2024 -238.24 % . Year-over-Year EBIT Growth of Labgenomics Co was 2023 -110.07 % . It decreases by 116.45% lower compared to the previous year.

The Labgenomics Co EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2017
-34,533.39 KRW
Jan 1, 2018
-9.80 KRW
Jan 1, 2019
124.05 KRW
Jan 1, 2020
6,766.42 KRW
Jan 1, 2021
96.21 KRW
Jan 1, 2022
-36.66 KRW
Jan 1, 2023
-110.07 KRW
Jan 1, 2024
-238.24 KRW
The Labgenomics Co EBIT Growth history
YEAREBIT GrowthYoY
-238.24 %+116.45%
-110.07 %+200.27%
-36.66 %-138.10%
96.21 %-98.58%
6,766.42 %+5,354.44%
124.05 %-1,366.15%
-9.80 %-99.97%
-34,533.39 %+34,152.00%
-100.82 %+66.54%
-60.54 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Labgenomics Co Stock analysis

What does Labgenomics Co do? LabGenomics Co., Ltd. generates revenue through the provision of in vitro diagnostic (IVD) products and services. The company offers general diagnostic check services, molecular diagnostic check services, and research and development services, alongside IVD products such as DNA chips and PCR kits. Its diagnostic services include examinations for breast cancer and colorectal cancer, while its biosensor solutions target point of care testing (POCT). Additionally, LabGenomics sells healthy food as part of its product portfolio. The primary buyers of LabGenomics' services are healthcare institutions requiring diagnostic support, including hospitals and clinics. The company's molecular diagnostic services and cancer examinations are particularly sought after by medical facilities focused on specialized testing. Healthcare providers also purchase its biosensor solutions for immediate testing at the point of care. LabGenomics' product segments include IVD services, IVD products like DNA chips and PCR kits, cancer examination services, and healthy food. The company's molecular diagnostic services and cancer testing are key revenue drivers, while its biosensor for POCT and healthy food offerings serve complementary market segments. Labgenomics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Labgenomics Co stock

Year-over-Year EBIT Growth of Labgenomics Co is -238.24 % in 2024.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth Labgenomics Co since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's Labgenomics Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Growth — Labgenomics Co

Revenue GrowthRevenue CAGR 3YRevenue CAGR 5YRevenue CAGR 10YEarnings GrowthEPS GrowthEBIT GrowthEBIT CAGR 3YEBIT CAGR 5YEBIT CAGR 10YDividend GrowthFCF GrowthBook Value GrowthEarnings CAGR 3YEarnings CAGR 5YEarnings CAGR 10YEPS CAGR 3YEPS CAGR 5YEBITDA Growth YoYEBITDA CAGR 3YEBITDA CAGR 5YGross Profit GrowthOCF Growth YoYEmployee GrowthDividend CAGR 3YDividend CAGR 5YDividend CAGR 10YAsset GrowthEquity GrowthDebt GrowthCapEx GrowthFCF CAGR 3YFCF CAGR 5YMarket Cap GrowthShare Count Growth

All Key Metrics — Labgenomics Co